Recently, with the continued ongoing debate as to whether NAFLD is an active contributor that increases CVD risk, a two‐sample Mendelian randomization (MR) analysis using summary‐level data to assess the association between genetically predicted NAFLD (i.e., chronically elevated serum alanine aminotransferase levels [cALT], imaging‐based and biopsy‐confirmed NAFLD), and risk of coronary artery disease was undertaken.46 Here, CETN2 is linked to metabolic dysfunction-associated steatotic liver disease.